Patient Profile Presentation: A 64-Year-Old Woman With Recurrent Endometrial Cancer

Opinion
Video

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Related Videos
Michael J. Birrer, MD, PhD
Bhavana Pothuri, MD
Alessandro Santin, MD
Bhavana Pothuri, MD
Megan Hitchins, PhD
Megan Hitchins, PhD
Experts on gynecologic cancers
Experts on gynecologic cancers
Experts on gynecologic cancers
Related Content

FDA Grants Priority Review to Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

September 20th 2023

FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer

August 28th 2023

Tisotumab Vedotin Improves OS in Recurrent/Metastatic Cervical Cancer

September 5th 2023

FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer

April 13th 2023

Geptanolimab Elicits Durable Responses and Acceptable Safety in PD-L1+ Cervical Cancer

August 29th 2023

TROP2 Expression Predicts Sacituzumab Govitecan Activity in Recurrent Endometrial Cancer

August 24th 2023

FDA Grants Priority Review to Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

September 20th 2023

FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer

August 28th 2023

Tisotumab Vedotin Improves OS in Recurrent/Metastatic Cervical Cancer

September 5th 2023

FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer

April 13th 2023

Geptanolimab Elicits Durable Responses and Acceptable Safety in PD-L1+ Cervical Cancer

August 29th 2023

TROP2 Expression Predicts Sacituzumab Govitecan Activity in Recurrent Endometrial Cancer

August 24th 2023

FDA Grants Priority Review to Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

September 20th 2023

FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer

August 28th 2023

Tisotumab Vedotin Improves OS in Recurrent/Metastatic Cervical Cancer

September 5th 2023

FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer

April 13th 2023

Geptanolimab Elicits Durable Responses and Acceptable Safety in PD-L1+ Cervical Cancer

August 29th 2023

TROP2 Expression Predicts Sacituzumab Govitecan Activity in Recurrent Endometrial Cancer

August 24th 2023